Pyxis Oncology Inc. reported financial results for the second quarter of 2025, with revenues reaching $2.8 million, a significant increase from $0 in the same quarter of 2024. This revenue was primarily generated from a $3 million milestone related to the regulatory approval of suvemcitug in China, partially offset by $0.2 million in taxes. The company's net loss for the quarter ended June 30, 2025, was $18.4 million, compared to a net loss of $17.3 million in the corresponding quarter of the previous year. Excluding non-cash stock-based compensation expenses, the net loss stood at $15.3 million for the quarter, compared to $14.4 million in the prior year. Research and development expenses increased to $17.1 million from $14.0 million year-over-year, driven by heightened manufacturing and clinical trial-related expenses. Conversely, general and administrative expenses decreased to $5.4 million from $6.1 million, owing to reductions in corporate insurance, facilities costs, and professional fees. As of June 30, 2025, Pyxis Oncology had cash, cash equivalents, and short-term investments totaling $90.4 million. The company anticipates that this financial position will support its operational needs into the second half of 2026.